Both Lilly and Novo Nordisk are experiencing unprecedented growth thanks to their weight loss medications. However, Lilly also treats cancer, plaque psoriasis, Alzheimer's disease, eczema ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Enter Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the makers behind blockbuster glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro, Zepbound, Ozempic, and Wegovy -- all of which are ...

Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity. The proposal ...

In order to do so, it's important to find reliable businesses that are also on a growth trajectory. Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have attracted a lot of attention over the past ...

In the time since, though, some analysts have said the reaction is overblown, particularly for weight-loss drugmakers like Wegovy, and Ozempic maker Novo Nordisk and Zepbound maker Eli Lilly.

Earnings Report 1.900 USD Q4 2021 Earnings Release 02/03/2022 Indices Commodities Currencies Stocks ...